Effect of a food supplement (Aquilea Colesterol®) on plasma total cholesterol and LDL cholesterol concentrations

Submission date	Recruitment status No longer recruiting	Prospectively registered		
07/11/2018		Protocol		
Registration date	Overall study status	Statistical analysis plan		
20/02/2019	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
04/10/2019	Nutritional, Metabolic, Endocrine			

Plain English summary of protocol

Background and study aims

High levels of cholesterol in the blood can cause injury to the arteries, which may lead to a heart attack or stroke. Therefore, it is important to reduce these levels of cholesterol. One strategy for this is to improve lifestyle choices and use food supplements. Certain food supplements, which contain compounds called phytosterols or monacolin (from red rice), are already available on the market and have cholesterol-reducing effects.

This study aims to look at the effectiveness of a new food supplement, Aquilea Colesterol®, containing monacolin, phytosterols and two other cholesterol-reducing compounds (olive hydroxytyrosol and vitamin E) on the levels of cholesterol in the blood.

Who can participate?

Adults aged over 35 years with high cholesterol

What does the study involve?

Participants will be randomly allocated to one of two groups, either the intervention group or the control group. The intervention group will be given the Aquilea Colesterol® supplement, to be taken daily before their main meal for 90 days. The control group will be given a placebo supplement to take daily before their main meal for 90 days. All participants will be asked to attend clinical appointments just before beginning the study, after 4 weeks, and then for a final visit after 12 weeks, where they will be asked to complete a fasted blood test.

What are the potential risks and benefits of the study?

The possible benefit of participating is that individuals in the intervention group may have reduced cholesterol levels. The possible benefits of participating in the study are pain and bruising from the blood test, and potential mild gastrointestinal or muscular symptoms related to taking the food supplement.

Where is the study run from?

Outpatient clinic of the Department of Internal Medicine Service of Hospital Clinic of Barcelona (Spain)

When is the study starting and how long is it expected to run for? September 2017 to February 2019

Who is funding the study? Uriach Consumer Healthcare S.L. (Spain)

Who is the main contact? Dr. Ramon Estruch restruch@clinic.cat

Contact information

Type(s)

Scientific

Contact name

Dr Ramon Estruch

Contact details

Department of Internal Medicine, Hospital Clinic, Villarroel, 170 Barcelona Spain 08036 +34 (0)932279365 restruch@clinic.cat

Type(s)

Scientific

Contact name

Dr Monica Domenech

Contact details

Villarroel 170 Barcelona Spain 08036

Additional identifiers

Protocol serial number 02/2018

Study information

Scientific Title

Effect of Aquilea Cholesterol® on plasma cholesterol and lipid profile

Study objectives

The intake of Aquilea Cholesterol® food supplement (10 mg monacolin K, 1.5 g of phytosterols, 5 mg of olive hydroxytyrosol and 24 mg of vitamin E) is able to significantly reduce the concentration of total cholesterol and LDL cholesterol in patients with hypercholesterolemia.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Institutional Review Board of the Hospital Clínic of Barcelona, 07/02/2018, HCB/2017/0994

Study design

Interventional single-blinded randomised placebo-controlled parallel group pilot study

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Hypercholesterolemia

Interventions

Participants will be randomly allocated to either the intervention or control group in a 1:1 ratio using a computer-generated random number sequence.

Participants allocated to the intervention group receive 10 mg monacolin K, 1.5 g phytosterols, 5 mg olive hydroxytyrosol and 24 mg vitamin E in a liquid stick (Aquilea Colesterol®). This food supplement should be taken daily for 90 days, preferably before the main meal.

Participants in the control group will receive 1 liquid stick of placebo per day, again to be taken daily for 90 days, preferably before the main meal.

There will be appointments at the baseline, and after 4 and 12 weeks.

Intervention Type

Other

Primary outcome(s)

- 1. Lipid profile change, assessed at the baseline and after 12 weeks:
- 1.1. Total cholesterol, assessed using enzymatic procedures
- 1.2. HDL cholesterol, assessed by precipitation with phosphotungistic acid and magnesium chloride using the Advia 2400
- 1.3. Triglycerides, assessed using enzymatic procedures
- 1.4. LDL cholesterol, assessed using the following formula: LDL cholesterol = total cholesterol HDL cholesterol (triglycerides/5))
- 2. Change in oxidised LDLs, assessed using ELISA with the mAb-4E6 antibody at the baseline and after 12 weeks
- 3. Blood pressure, assessed using a validated semiautomatic oscilliometer at the baseline and after 4 and 12 weeks

Key secondary outcome(s))

- 1. Change in cardiovascular risk, assessed using the REGICOR score at the baseline and after 12 weeks
- 2. Change in biomarkers of systemic inflammation, assessed using ELISA at the baseline and after 12 weeks:
- 2.1. Plasma C-reactive protein (CRP)
- 2.2. Interleukin-6 (IL-6)

Completion date

20/02/2019

Eligibility

Key inclusion criteria

- 1. Aged 35-75 years
- 2. Low (<5%) or moderate (5-9%) coronary risk according to REGICOR risk tables
- 3. Total cholesterol values between 200-250 mg/dl according to previous analytical test
- 4. LDL cholesterol values >115 mg/dl without lipid-lowering treatment

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

ΔII

Total final enrolment

40

Key exclusion criteria

- 1. Using or previously used lipid-lowering treatment (statins, fibrates, resins, ezetimibe) and/or any other product with a lipid-lowering effect (red rice, plant sterols) in the previous 3 months
- 2. Indication for treatment with lipid-lowering drugs
- 3. Previous cardiovascular disease (myocardial infarction, angina, stroke, peripheral arterial disease)
- 4. High (10-14%) or very high (≥15%) coronary risk according to REGICOR risk tables
- 5. BMI ≥30 kg/m²

Date of first enrolment

01/05/2018

Date of final enrolment

15/10/2018

Locations

Countries of recruitment

Spain

Study participating centre Hospital Clinic of Barcelona C/Villarroel 170

C/Villarroel 170 Barcelona Spain 08036

Sponsor information

Organisation

Uriach Consumer Healthcare S.L.

ROR

https://ror.org/04jfxq686

Funder(s)

Funder type

Industry

Funder Name

Uriach Consumer Healthcare S.L.

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be stored in a non-publically available repository.

IPD sharing plan summary

Stored in repository

Study outputs

Output type	Details	Date created Date added Peer reviewed? Patient-facing?

Results article results 26/04/2019 04/10/2019 Yes No

Participant information sheet 11/11/2025 No Yes